Investor Alert

New York Markets After Hours

Market Pulse Archives

May 4, 2021, 7:53 a.m. EDT

Bausch reports a $610 million loss in the first quarter of the year

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Bausch Health Cos. Inc. (BHC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Bausch Health Cos. Inc. /zigman2/quotes/207248436/composite BHC +8.04% were down 2.3% in premarket trading on Tuesday after the company said it faced continued pressure on sales from the COVID-19 pandemic into the first quarter of this year. Bausch had a loss of $610 million, or $1.71 per share, in the first quarter of 2021, compared with a loss of $152 million, or 43 cents per share, in the same quarter a year ago. Bausch did not provide adjusted earnings per share for the quarter. The company reported $2.02 billion in sales for the first quarter of the year, up from $2.01 billion in the like quarter a year ago. The FactSet consensus was $2.05 billion. Much of Bausch's business continues to be affected by the pandemic, it said, citing declining sales of irritable bowel syndrome drug Xifaxin and lower sales of eye-care products for the quarter. Bausch said it still plans to move forward with spinning off the Bausch + Lomb eye-care business, which had $881 million in sales for the quarter, up from $875 million in the first quarter of 2020. Bausch's other business focuses on pharmaceuticals; it had $1.14 billion in sales, compared with $1.13 billion in the same quarter a year ago. Bausch's stock has gained 51.0% since the start of the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.08% is up 11.6%.

$ 28.21
+2.10 +8.04%
Volume: 5.06M
Sept. 21, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$9.37 billion
Rev. per Employee
-3.54 -0.08%
Volume: 1.91B
Sept. 21, 2021 4:20p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.